allitem_id Publication Year Title Author(s) 1 Jan-2024 Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Hofman, Michael S; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Buteau, James P; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew J 2 8-Jun-2023 Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial. Tremblay, Samuel; Alhogbani, Mofarej; Weickhardt, Andrew J 3 Nov-2022 PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Buteau, James P; Martin, Andrew J; Emmett, Louise; Iravani, Amir; Sandhu, Shahneen; Joshua, Anthony M; Francis, Roslyn J; Zhang, Alison Y; Scott, Andrew M 4 27-Feb-2021 [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Hofman, Michael S; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew J 5 15-Sep-2020 First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. Scott, Andrew M 6 Sep-2019 Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Kramer, Gerbrand M; Yaqub, Maqsood; Vargas, Herbert A; Schuit, Robert C; Windhorst, Albert D; van den Eertwegh, Alfonsus J M; van der Veldt, Astrid A M; Bergman, Andries M; Burnazi, Eva M; Lewis, Jason S; Chua, Sua; Staton, Kevin D; Beattie, Brad J; Humm, John L; Davis, Ian D; Weickhardt, Andrew J 7 Sep-2019 The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Metser, Ur; Chua, Sue; Ho, Bao; Punwani, Shonit; Johnston, Edward; Pouliot, Frederic; Tau, Noam; Hawsawy, Asmaa; Anconina, Reut; Bauman, Glenn; Hicks, Rodney J; Weickhardt, Andrew J 8 2019 A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes. Emmett, Louise; Metser, Ur; Bauman, Glenn; Hicks, Rodney J; Weickhardt, Andrew; Davis, Ian D; Punwani, Shonit; Pond, Gregory R; Chua, Sue Siew-Chen; Ho, Bao; Johnston, Edward; Pouliot, Frederic; Scott, Andrew M 9 Oct-2018 Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M 10 2018 Reproducibility and repeatability of semi-quantitative18F-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study. Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M 11 Aug-2016 Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module Ackermann, Uwe 12 8-Apr-2015 Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions. Chang, Joe H; Lim Joon, Daryl 13 1-Feb-2014 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Mertens, Laura S; Mir, M Carmen; Scott, Andrew M 14 6-Nov-2013 Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Chang, Joe H; Lim Joon, Daryl 15 30-May-2012 Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans. Chang, Joe H; Lim Joon, Daryl 16 7-Dec-2011 Oncology health information quality on the Internet: a multilingual evaluation. Lawrentschuk, Nathan; Sasges, Deborah; Tasevski, Robert; Abouassaly, Robert; Scott, Andrew M 17 18-May-2011 Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Chang, Joe H; Joon, Daryl Lim; Lee, Sze Ting 18 12-Jun-2009 Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Lawrentschuk, Nathan; Lee, Fook-Thean; Jones, Gareth; Rigopoulos, Angela; Mountain, Angela; O'Keefe, Graeme J; Papenfuss, Anthony T; Bolton, Damien M 19 1-Jan-2009 Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Kelly, Marcus P; Lee, Sze Ting 20 1-Jun-2007 A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Scott, Andrew M
Loading...
2
0
20
0
false
0000-0002-6656-295x
@ONJCRI